publication venue for
- Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. 2018
- Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria. 2014
- Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.. 16. 2023
- Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.. 15. 2022
- Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.. 14. 2021
- Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.. 14. 2021
- Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.. 14. 2021
- A precision medicine classification for treatment of acute myeloid leukemia in older patients.. 14. 2021
- Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.. 14. 2021
- Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.. 14. 2021
- GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.. 13. 2020
- Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.. 11. 2018
- Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.. 11. 2018
- Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.. 11. 2018
- miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.. 11. 2018
- Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).. 10. 2017
- Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency.. 10. 2017
- Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.. 10. 2017
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.. 10. 2017
- Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.. 9. 2016
- High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. 8. 2015
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.. 7. 2014
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.. 7. 2014
- Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias.. 2. 2009
- Temozolomide and cisplatin in relapsed/refractory acute leukemia.. 2. 2009
- Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types. 2023
- A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors. 2022
- XPO1-dependent nuclear export as a target for cancer therapy. 2020
- Biomarker-driven management strategies for peripheral T cell lymphoma. 2020
- Light chain (AL) amyloidosis: update on diagnosis and management. 2011
- Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. 2023
- Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells. 2022
- The management of metastatic GIST: current standard and investigational therapeutics. 2021